Your browser doesn't support javascript.
loading
Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer: The APPROVE Randomized Clinical Trial.
Wang, Tiantian; Tang, Jie; Yang, Hongying; Yin, Rutie; Zhang, Jingru; Zhou, Qi; Liu, Ziling; Cao, Lanqin; Li, Li; Huang, Yi; Jiang, Kui; Wang, Wei; She, Fenglin; Guan, Ni; Hou, Zhiguo; Li, Ning; Wu, Lingying.
Afiliação
  • Wang T; Department of Gynecologic Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Tang J; Department of Gynecologic Oncology, Hunan Cancer Hospital, Central South University, Changsha, China.
  • Yang H; Department of Gynecology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Provincial Cancer Center, Kunming, China.
  • Yin R; Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China.
  • Zhang J; Department of Gynecology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, China.
  • Zhou Q; Department of Gynecologic Oncology, Chongqing University Cancer Hospital, Chongqing, China.
  • Liu Z; Department of Oncology Center, The First Hospital of Jilin University, Changchun, China.
  • Cao L; Department of Gynecology, Xiangya Hospital, Central South University, Changsha, China.
  • Li L; Department of Gynecologic Oncology, Guangxi Medical University Affiliated Tumor Hospital, Nanning, China.
  • Huang Y; Department of Gynecologic Oncology, Hubei Cancer Hospital, Wuhan, China.
  • Jiang K; Department of Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, China.
  • Wang W; Department of Gynecology, Peking Union Medical College Hospital, Beijing, China.
  • She F; Jiangsu Hengrui Pharmaceuticals Co Ltd, Shanghai, China.
  • Guan N; Jiangsu Hengrui Pharmaceuticals Co Ltd, Shanghai, China.
  • Hou Z; Jiangsu Hengrui Pharmaceuticals Co Ltd, Shanghai, China.
  • Li N; Department of Gynecologic Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Wu L; Department of Gynecologic Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
JAMA Oncol ; 8(8): 1169-1176, 2022 08 01.
Article em En | MEDLINE | ID: mdl-35771546
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Fator A de Crescimento do Endotélio Vascular Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Fator A de Crescimento do Endotélio Vascular Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2022 Tipo de documento: Article